Measuring Neuroadaptations in Response to Very Low Nicotine Content Cigarettes

July 29, 2024 updated by: Andrea Hobkirk, PhD, Milton S. Hershey Medical Center
The overall goal of this study is to determine if switching to very low nicotine content cigarettes changes the function of brain circuitry involved in incentive salience and executive control among dependent smokers.

Study Overview

Detailed Description

In a double-blind, randomized controlled trial, dependent smokers will be randomized to a 6-week very low nicotine content (VLNC) cigarette condition (N=50) or a 6-week normal nicotine content cigarette control condition (NNC; N=25). Participants will undergo functional magnetic resonance imaging (fMRI) scans at baseline and 6-weeks to investigate the nicotine-related modulation of brain circuitry involved in incentive salience valuation and executive control. Imaging tasks will engage the incentive salience of smoking cues and non-smoking rewards and executive control functions to identify changes in functional activity within, and effective connectivity between, known salience and executive control brain circuitry. A novel fMRI task using specialized odor presentation equipment and fMRI sequences will assess neural cue reactivity to smoke odors.

Study Type

Interventional

Enrollment (Actual)

34

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Pennsylvania
      • Hershey, Pennsylvania, United States, 17033
        • Penn State Health

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

21 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • 21-60 years old
  • Smoke >5 cigarettes per day
  • >1 year of daily smoking
  • No quit attempt in prior month and not planning to quit smoking within next 3 months
  • Able to understand and consent to study procedures
  • High school or lower educational attainment or annual household income < $50,000
  • Plan to live in local area next 3 months
  • Women not pregnant or nursing and taking steps to avoid pregnancy
  • Able to read and write in English
  • Access to computer with internet service that allows for Zoom

Exclusion Criteria:

  • Use of non-cigarette tobacco products in the past 7 days
  • Use of illicit substances more than once a week in the past 3 months (excluding marijuana)
  • Current alcohol abuse impairing participation
  • MRI safety contraindications (e.g., metal implants, claustrophobia)
  • Unstable or significant medical conditions (e.g., chronic obstructive pulmonary disorder, coronary heart disease)
  • Major neurological conditions or brain trauma
  • Major surgeries planned in next 3 months
  • Use of smoking cessation medication in prior month (e.g., varenicline, patch)
  • Uncontrolled serious mental illness, suicidality, or inpatient psychiatric hospitalization in the past 6 months
  • Unwillingness to provide urine samples
  • Unwilling to smoke study assigned cigarettes for the remainder of the trial
  • Plans to move or take extended travel out of the area in the next 3 months
  • Any other condition or situation that would, in the investigator's opinion, make it unlikely that the participant could comply with the study protocol
  • Self-reported color blindness
  • Left-handedness
  • Smell dysfunction as determined via standardized assessment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Very low nicotine content cigarettes
Research cigarettes with very low nicotine content (0.03 mg/cigarette) compared to usual brand cigarettes.
Very low nicotine content cigarettes
Placebo Comparator: Normal nicotine content cigarettes
Research cigarettes with normal nicotine content (0.8 mg/cigarette) similar to usual brand cigarettes.
Normal nicotine content cigarettes

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Blood Oxygen Level Dependent (BOLD) Signal Collected by Functional Magnetic Resonance Imaging (fMRI) During Monetary Delay Discounting Task
Time Frame: Change in BOLD signal from baseline to the 6-week visit.
Change from baseline to 6-weeks post-intervention in percentage of BOLD signal during hard vs. no choice conditions on a monetary delay discounting task in a left-sided cortical brain region encompassing the central opercular and dorsolateral prefrontal cortices.
Change in BOLD signal from baseline to the 6-week visit.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Self-reported Cigarettes Per Day
Time Frame: Average cigarettes per day during week 1 subtracted from average cigarettes per day during week 6.
Difference in week 6 mean minus week 1 mean of cigarettes used per day reported by participants on daily logs.
Average cigarettes per day during week 1 subtracted from average cigarettes per day during week 6.
Change in Percentage of Immediate Choices on Monetary Delay Discounting Task
Time Frame: Changes from baseline to 6-weeks post intervention.
A difference score (6-weeks minus baseline) of the percentage of trials where the immediate (vs. delayed) monetary option was chosen out of all task trials during the monetary delay discounting task that was completed outside of the MRI scan.
Changes from baseline to 6-weeks post intervention.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Andrea Hobkirk, PhD, Milton S. Hershey Medical Center

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 20, 2020

Primary Completion (Actual)

June 23, 2023

Study Completion (Actual)

June 23, 2023

Study Registration Dates

First Submitted

July 18, 2018

First Submitted That Met QC Criteria

August 1, 2018

First Posted (Actual)

August 2, 2018

Study Record Updates

Last Update Posted (Actual)

August 20, 2024

Last Update Submitted That Met QC Criteria

July 29, 2024

Last Verified

July 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Tobacco Dependence

Clinical Trials on Very low nicotine content cigarettes

Subscribe